TCR2 Therapeutics Inc. buy quelbe60
Start price
16.10.22
/
50%
€1.68
Target price
16.10.23
-
Performance (%)
-6.83%
End price
30.10.22
€1.56
Summary
This prediction ended on 30.10.22 with a price of €1.56. With a performance of -6.83%, the BUY prediction by quelbe60 finished with a loss. quelbe60 has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| TCR2 Therapeutics Inc. | - | - | - | - |
| iShares Core DAX® | 0,44 % | 3,03 % | 12,68 % | 49,79 % |
| iShares Nasdaq 100 | 3,82 % | 4,07 % | 33,15 % | 88,25 % |
| iShares Nikkei 225® | 1,15 % | 6,90 % | 45,49 % | 61,92 % |
| iShares S&P 500 | 2,37 % | 2,68 % | 25,69 % | 63,54 % |
According to quelbe60 what are the pros and cons of TCR2 Therapeutics Inc. for the foreseeable future?
Pros
Could be very worthwhile Investment >20% year
Cons
Comments by quelbe60 for this prediction
In the thread Tcr2 Therapeutics Inc. diskutieren
Buy TCR2 Therapeutics Inc.